With the increased survival of HIV-infected patients, there
have emerged a number of unexpected consequences of chronic illness and drugs
adverse events, especially in the form of metabolic disease .
Available data suggest the presence of an accelerated
process of coronary atherosclerosis in this population due to multiple
factors, including a higher prevalence (compared with non–HIV-infected
patients) of conventional risk factors, emerging risk factors (chronic
inflammation, immune activation, and senescence related to HIV infection
itself), and the role of antiretroviral therapy (ART), regarding metabolic
syndrome as one of the major problems . Some studies have showed that the
prevalence of metabolic syndrome was higher among HIV-infected patients on ART
than among non-HIV-infected healthy controls (15.8 vs. 3.2%). A high
incidence of diabetes mellitus (DM) and impaired fasting glucose (IFG) has been
detected in HIV-infected patients receiving ART. Another studies have
found relationship between some classes of antiretroviral
(ARV) drugs such as protease inhibitors (PIs) and nucleos(t)ide
retrotranscriptase inhibitors (NRTIs) with a higher frequency of new-onset DM
and IFG.
We conducted a retrospective cohort from 1 June 2014 to 30
December 2014 of HIV-1 treatment naïve-infected adults who started therapy for
the first time. Dyslipidemia (total cholesterol and triglycerides) and fasting
plasma glucose, before and 48 weeks after starting ART were collected.
Patients
The hospital institutional review board and ethics committee
reviewed and approved this study (reference number R-2015-3502-70).
No comments:
Post a Comment